Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

Area of Science:

• Neuroscience
• Neurology
• Biochemistry

Background:

• The amyloid-beta (Aβ) cascade hypothesis posits that Aβ accumulation drives Alzheimer disease (AD) pathogenesis.
• Current therapeutic strategies for AD primarily target Aβ production, clearance, and aggregation.
• Despite extensive research, drugs targeting Aβ have largely failed to demonstrate clinical efficacy in AD patients.

Purpose of the Study:

• To critically evaluate the amyloid-beta cascade hypothesis in light of recent physiological findings.
• To explore alternative explanations for Aβ accumulation in the context of Alzheimer disease.
• To identify potential new therapeutic avenues for Alzheimer disease beyond Aβ-centric approaches.

Main Methods:

• Review of recent literature on amyloid-beta physiology and Alzheimer disease.
• Analysis of clinical trial outcomes for Aβ-targeting therapies.
• Synthesis of emerging evidence suggesting compensatory roles for Aβ.

Main Results:

• Numerous Aβ-targeting drug candidates have failed to show significant clinical benefit in AD trials.
• Monoclonal antibodies against neurotoxic Aβ forms are in late-stage clinical trials.
• Emerging data suggest that Aβ accumulation might be a compensatory mechanism rather than the primary pathological event.

Conclusions:

• The traditional amyloid-beta cascade hypothesis may require revision.
• Alternative therapeutic strategies for Alzheimer disease are urgently needed.
• Understanding the normal function of Aβ is crucial for developing effective treatments.